Phenotype Assessment of Blood and Airway Eosinophils in Patients With COPD and Asthma

• Conditions: COPD Asthma; Eosinophilic Asthma

• Registration Number: NCT05398133
• Lead Sponsor: Medical University of Warsaw

Brief Summary

Around 1/3 of patients with COPD have elevated eosinophil levels. However, the role of eosinophils in COPD has not been yet understood and is probably different in COPD and in asthma. The aim of this study was to assess the expression of selected surface markers on eosinophils and to assess the gene expression in eosinophils in COPD and asthma patients. We are planning to enrol 12 COPD, 12 asthma and 12 control subjects. Patients will undergo routine clinical assessment, spirometry, blood sampling and sputum induction. Eosinophils will be isolated from blood and sputum. Surface markers on eosinophils will be assessed in flow cytometry, gene expression will be assessed by RNAseq.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-09-01
• Status Verified: 2022-05
• Study First Submitted: 2022-05-19
• Study First Submitted QC: 2022-05-27
• Last Update Submitted: 2022-05-27
• Study First Posted: 2022-05-31
• Last Update Posted: 2022-05-31
• Primary Completion: 2022-06
• Study Completion: 2022-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

• Diagnosis of COPD according to GOLD 2019 or asthma according to GINA 2021
• Peripheral blood eosinophil count ≥ 100 / μL
• Age ≥40 years (COPD), ≥18 years (asthma)
• History of cigarette smoking: ≥10 pack-years (for COPD)
• Stable disease period (at least 3 months without exacerbation)
• Exclusion of parasitic diseases
• Informed consent to participate in the study

Exclusion Criteria

• COPD and asthma overlap
• Use of systemic corticosteroids in the 3 months prior to the study
• Respiratory infection or exacerbation in the 3 months prior to the study
• Acute and chronic respiratory failure
• Concomitant diagnoses: systemic connective tissue diseases, malignant neoplasms, severe and / or uncontrolled cardiovascular diseases
• Use of immunosuppressive or immunomodulating drugs in the 3 months preceding the study
• Contraindications to sputum induction
• No consent to participate in the study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
expression of surface markers	performed up to 3 months after blood and sputum collection	expression of CD125, CD62L, CD66b, CD193, CD11b, CD14

Trial Locations

Locations (1)

Medical University of Warsaw, Banacha Hospital; 🇵🇱 Warsaw, Poland